EBS vs. CLDX, MNKD, INVA, DVAX, NVAX, OPK, GERN, RGLS, ZBIO, and MYGN
Should you be buying Emergent BioSolutions stock or one of its competitors? The main competitors of Emergent BioSolutions include Celldex Therapeutics (CLDX), MannKind (MNKD), Innoviva (INVA), Dynavax Technologies (DVAX), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Regulus Therapeutics (RGLS), Zenas Biopharma (ZBIO), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.
Emergent BioSolutions vs. Its Competitors
Celldex Therapeutics (NASDAQ:CLDX) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, community ranking, institutional ownership, media sentiment, analyst recommendations, valuation and risk.
Celldex Therapeutics currently has a consensus price target of $53.90, indicating a potential upside of 164.86%. Emergent BioSolutions has a consensus price target of $14.33, indicating a potential upside of 116.84%. Given Celldex Therapeutics' higher probable upside, research analysts clearly believe Celldex Therapeutics is more favorable than Emergent BioSolutions.
Celldex Therapeutics has higher earnings, but lower revenue than Emergent BioSolutions. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.
78.4% of Emergent BioSolutions shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by insiders. Comparatively, 3.2% of Emergent BioSolutions shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Emergent BioSolutions has a net margin of -18.55% compared to Celldex Therapeutics' net margin of -1,544.32%. Emergent BioSolutions' return on equity of -9.91% beat Celldex Therapeutics' return on equity.
Celldex Therapeutics has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
Celldex Therapeutics received 198 more outperform votes than Emergent BioSolutions when rated by MarketBeat users. Likewise, 75.27% of users gave Celldex Therapeutics an outperform vote while only 66.82% of users gave Emergent BioSolutions an outperform vote.
In the previous week, Celldex Therapeutics had 15 more articles in the media than Emergent BioSolutions. MarketBeat recorded 15 mentions for Celldex Therapeutics and 0 mentions for Emergent BioSolutions. Celldex Therapeutics' average media sentiment score of 1.04 beat Emergent BioSolutions' score of 0.00 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Summary
Celldex Therapeutics beats Emergent BioSolutions on 11 of the 19 factors compared between the two stocks.
Get Emergent BioSolutions News Delivered to You Automatically
Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Emergent BioSolutions Competitors List
Related Companies and Tools
This page (NYSE:EBS) was last updated on 6/13/2025 by MarketBeat.com Staff
